Twist Bioscience Co. (NASDAQ:TWST) CFO Sells $185,536.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 4,160 shares of the company's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $185,536.00. Following the sale, the chief financial officer now owns 89,237 shares in the company, valued at $3,979,970.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Wednesday, October 9th, Adam Laponis sold 856 shares of Twist Bioscience stock. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36.

Twist Bioscience Price Performance

TWST stock traded down $0.12 on Friday, reaching $45.40. The company's stock had a trading volume of 638,602 shares, compared to its average volume of 941,083. Twist Bioscience Co. has a 52 week low of $15.85 and a 52 week high of $60.90. The company has a market capitalization of $2.66 billion, a P/E ratio of -11.88 and a beta of 1.78. The firm has a fifty day moving average of $43.69 and a two-hundred day moving average of $45.64.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TWST. Barclays reduced their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Robert W. Baird raised their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience currently has an average rating of "Moderate Buy" and an average price target of $51.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Intech Investment Management LLC bought a new stake in shares of Twist Bioscience during the third quarter valued at about $714,000. Jennison Associates LLC increased its stake in Twist Bioscience by 29.6% during the 3rd quarter. Jennison Associates LLC now owns 377,894 shares of the company's stock valued at $17,073,000 after buying an additional 86,399 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the 3rd quarter valued at about $43,992,000. Chesapeake Capital Corp IL raised its position in shares of Twist Bioscience by 27.9% during the 3rd quarter. Chesapeake Capital Corp IL now owns 6,176 shares of the company's stock worth $287,000 after buying an additional 1,347 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Twist Bioscience by 7.7% in the 3rd quarter. Victory Capital Management Inc. now owns 331,809 shares of the company's stock worth $14,991,000 after acquiring an additional 23,638 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.